Literature DB >> 33855119

Preparation and Characterization of Poly(2-oxazoline) Micelles for the Solubilization and Delivery of Water Insoluble Drugs.

Natasha Vinod1,2, Duhyeong Hwang1, Salma H Azam3, Amanda E D Van Swearingen3, Elizabeth Wayne1, Sloane Christian Fussell4, Marina Sokolsky-Papkov1, Chad V Pecot3,5,6, Alexander V Kabanov1,7.   

Abstract

Many new drug development candidates are highly lipophilic compounds with low water solubility. This constitutes a formidable challenge for the use of such compounds for cancer therapy, where high doses and intravenous injections are needed ( Di et al., 2012 ). Here, we present a poly(2-oxazoline) polymer (POx)-based nanoformulation strategy to solubilize and deliver hydrophobic drugs. POx micelles are prepared by a simple thin-film hydration method. In this method, the drug and polymer are dissolved in a common solvent and allowed to mix, following which the solvent is evaporated using mild heating conditions to form a thin film. The micelles form spontaneously upon hydration with saline. POx nanoformulation of hydrophobic drugs is unique in that it has a high drug loading capacity, which is superior to micelles of conventional surfactants. Moreover, multiple active pharmaceutical ingredients (APIs) can be included within the same POx micelle, thereby enabling the codelivery of binary as well as ternary drug combinations ( Han et al., 2012 ; He et al., 2016 ).
Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Active pharmaceutical ingredients; Lipophilic; Nanoformulation; Poly(2-oxazoline); Polymeric micelles; Surfactants

Year:  2021        PMID: 33855119      PMCID: PMC8032494          DOI: 10.21769/BioProtoc.3959

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  7 in total

Review 1.  Bridging solubility between drug discovery and development.

Authors:  Li Di; Paul V Fish; Takashi Mano
Journal:  Drug Discov Today       Date:  2011-11-26       Impact factor: 7.851

2.  Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs.

Authors:  Robert Luxenhofer; Anita Schulz; Caroline Roques; Shu Li; Tatiana K Bronich; Elena V Batrakova; Rainer Jordan; Alexander V Kabanov
Journal:  Biomaterials       Date:  2010-03-26       Impact factor: 12.479

Review 3.  Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions.

Authors:  Urvi H Gala; Dave A Miller; Robert O Williams
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-31       Impact factor: 10.680

4.  Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles.

Authors:  Yingchao Han; Zhijian He; Anita Schulz; Tatiana K Bronich; Rainer Jordan; Robert Luxenhofer; Alexander V Kabanov
Journal:  Mol Pharm       Date:  2012-06-28       Impact factor: 4.939

5.  A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity.

Authors:  Zhijian He; Xiaomeng Wan; Anita Schulz; Herdis Bludau; Marina A Dobrovolskaia; Stephan T Stern; Stephanie A Montgomery; Hong Yuan; Zibo Li; Daria Alakhova; Marina Sokolsky; David B Darr; Charles M Perou; Rainer Jordan; Robert Luxenhofer; Alexander V Kabanov
Journal:  Biomaterials       Date:  2016-06-04       Impact factor: 12.479

6.  High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma.

Authors:  Natasha Vinod; Duhyeong Hwang; Salma H Azam; Amanda E D Van Swearingen; Elizabeth Wayne; Sloane Christian Fussell; Marina Sokolsky-Papkov; Chad V Pecot; Alexander V Kabanov
Journal:  Sci Adv       Date:  2020-06-17       Impact factor: 14.136

7.  Cheminformatics-driven discovery of polymeric micelle formulations for poorly soluble drugs.

Authors:  Vinicius M Alves; Duhyeong Hwang; Eugene Muratov; Marina Sokolsky-Papkov; Ekaterina Varlamova; Natasha Vinod; Chaemin Lim; Carolina H Andrade; Alexander Tropsha; Alexander Kabanov
Journal:  Sci Adv       Date:  2019-06-26       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.